BofA: Investors pour into bonds, pull back from crypto
Eric Crombez, the Executive Vice President and Chief Medical (TASE:BLWV) Officer at Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), recently executed a significant stock transaction. According to a recent SEC filing, Crombez sold 8,945 shares of common stock on March 3, 2025, at a weighted average price of $42.10 per share. This sale, conducted to cover tax withholdings due to the vesting of restricted stock units (RSUs), amounted to a total transaction value of approximately $376,584. The transaction price was slightly above the current market price of $41.10, with InvestingPro data showing the stock trading near its 52-week low of $37.02.
Additionally, Crombez acquired a total of 31,784 shares of common stock on March 1, 2025. These acquisitions included an award of restricted stock units under the company’s 2023 Incentive Plan and the conversion of performance stock units upon certification of performance metrics. These transactions were recorded at no cost per share. According to InvestingPro analysis, Ultragenyx maintains strong liquidity with a current ratio of 2.37, though the company operates with moderate debt levels. Get access to more detailed insider trading analysis and 7 additional ProTips with an InvestingPro subscription.
The filing also detailed a derivative transaction involving stock options, granting Crombez the right to buy 30,246 shares at an exercise price of $42.92, set to expire on March 1, 2035. With analyst targets ranging from $47 to $140 per share and InvestingPro’s Fair Value analysis suggesting the stock is currently undervalued, these options could represent significant future value.
In other recent news, Ultragenyx Pharmaceutical Inc. reported fourth-quarter 2024 earnings that surpassed expectations, driven by strong sales of Crysvita, Dojolvi, and Evkeeza, according to Canaccord Genuity. The company posted total revenue of $164.9 million, exceeding Goldman Sachs and Visible Alpha Consensus estimates. Ultragenyx has maintained its full-year 2025 revenue guidance between $640 million and $670 million, aligning with the new estimates from Goldman Sachs and Visible Alpha.
Cantor Fitzgerald reiterated its Overweight rating with a $118 price target, highlighting Ultragenyx’s gene therapy programs, including the DTX301 for OTC deficiency and setrusumab for osteogenesis imperfecta. H.C. Wainwright maintained a Buy rating with a $95 target following the FDA’s acceptance of the BLA for UX111, a gene therapy candidate for Sanfilippo syndrome type A, marking a significant milestone for the company.
Canaccord Genuity raised its price target to $136, reflecting confidence in Ultragenyx’s growth trajectory and potential product launches. Goldman Sachs also reiterated a Buy rating with a $78 price target, emphasizing the company’s promising pipeline, including the anticipated commercial launch of UX111. These developments underscore Ultragenyx’s strategic focus on addressing unmet medical needs through its diverse pipeline of therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.